This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: April 7, 2006
Last updated: November 29, 2010
Last verified: November 2010
Fibromyalgics frequently report sleep disturbances, in particular poor and unrefreshing sleep. Additionally, studies have reported that sleep problems, pain and mood disturbances are associated in patients with fibromyalgia. By improving the quality of sleep, complaints of poor and unrefreshing sleep, fatigue, pain, which are among the main components of this chronic pain disorder may be improved.

Condition Intervention Phase
Fibromyalgia Sleep Chronic Pain Drug: eplivanserin (SR46349) Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-center, Randomized, Double-blind, Placebo-controlled Study.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • refreshing quality of sleep measured by the patient sleep questionnaire [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • sleep parameters (maintenance, duration, induction and quality) [ Time Frame: 8 weeks ]

Enrollment: 205
Study Start Date: April 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
1 mg daily
Drug: eplivanserin (SR46349)
oral administration
Experimental: 2
5 mg daily
Drug: eplivanserin (SR46349)
oral administration
Placebo Comparator: 3 Drug: placebo
oral administration

Detailed Description:
The purpose of this research study is to investigate the effectiveness and safety of 2 doses of the investigational product in subjects with sleep disorders with fibromyalgia as compared to placebo (a substance which contains no active ingredient). The study will last approximately 70 days and will include 7 office visits.

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Each patient must fulfill the diagnosis criteria of fibromyalgia according to the American College of Rheumatology
  • Based on patient's information:
  • The patient must complain of unrefreshing sleep for at least 3 nights per week over the past month.
  • The patient spends at least 6.5 hours and not more than 9 hours, in bed, each night over the past 2 weeks.
  • Female patients of childbearing potential must have a confirmed negative pregnancy test at the end of the screening period and use an acceptable method of birth control throughout the study
  • Written, signed and dated informed consent must be obtained from each patient
  • Willing to abstain from taking any medication or treatment prohibited as per the protocol

Exclusion Criteria:

  • Females who are lactating or pregnant
  • Night shift workers, and individuals who nap 3 or more times per week over the preceding month (nap: intentionally sleeping for more than 20 minutes during the day).
  • Consumption of beverage with caffeine (i.e. tea, coffee, or cola) comprising more than 2 cups or glasses per day
  • Past or Current medical history of any significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00313885

United States, Arizona
Radiant Research
Phoenix, Arizona, United States, 85013
United States, California
San Diego Arthritis Medical Clinic
San Diego, California, United States, 92108
United States, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States, 32216
Miami Research Assoc., Inc.
Miami, Florida, United States, 33173
Renstar Medical Research
Ocala, Florida, United States, 34471
United States, Georgia
Comprehensive Neuroscience
Atlanta, Georgia, United States, 30328
United States, Indiana
Physicians Research Group
Indianapolis, Indiana, United States, 46250
United States, Kansas
Wichita Clinic PA
Wichita, Kansas, United States, 67208
United States, Nebraska
Westroads Medical Group
Omaha, Nebraska, United States, 68114
United States, Utah
Physicians Research Options
Ogden, Utah, United States, 84403
United States, Washington
Seattle Rheumatology Assoc.
Seattle, Washington, United States, 98104
Sanofi-Aventis Administrative Office
Laval, Canada
Sponsors and Collaborators
Study Director: ICD CSD Sanofi
  More Information

Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00313885     History of Changes
Other Study ID Numbers: ACT5400
Study First Received: April 7, 2006
Last Updated: November 29, 2010

Additional relevant MeSH terms:
Chronic Pain
Myofascial Pain Syndromes
Sleep Wake Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Mental Disorders
SR 46349B
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on June 23, 2017